Michael Wiederhorn
Stock Analyst at Oppenheimer
(4.78)
# 589
Out of 5,133 analysts
1106
Total ratings
59.5%
Success rate
10.7%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CHE Chemed | Reiterated: Buy | $625 | $550.20 | +13.60% | 120 | Nov 12, 2026 | |
| PACS PACS Group | Reiterated: Buy | $57 | $48.00 | +18.75% | 7 | Nov 10, 2026 | |
| CI The Cigna Group | Reiterated: Buy | $365 | $296.27 | +23.20% | 77 | Nov 6, 2026 | |
| EVH Evolent Health | Reiterated: Buy | $6 → $7 | $4.77 | +46.75% | 14 | Nov 6, 2026 | |
| GRDN Guardian Pharmacy Services | Reiterated: Buy | $49 | $49.38 | -0.77% | 9 | Nov 6, 2026 | |
| PNTG The Pennant Group | Reiterated: Buy | $40 → $50 | $35.91 | +39.24% | 19 | Nov 5, 2026 | |
| TDOC Teladoc Health | Reiterated: Buy | $7 → $10 | $8.69 | +15.07% | 32 | Nov 2, 2026 | |
| CYH Community Health Systems | Reiterated: Buy | $4 → $3.5 | $2.21 | +58.37% | 122 | Oct 30, 2026 | |
| ENSG The Ensign Group | Reiterated: Buy | $210 → $215 | $186.55 | +15.25% | 90 | Oct 29, 2026 | |
| HCSG Healthcare Services Group | Reiterated: Buy | $28 | $25.02 | +11.91% | 2 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $405 → $475 | $443.68 | +7.06% | 81 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $53 | $31.77 | +66.82% | 1 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $520 → $485 | $500.66 | -3.13% | 96 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $405 → $500 | $405.13 | +23.42% | 88 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $155 | $123.72 | +25.28% | 113 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $58 | $70.27 | -17.46% | 163 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $89.79 | n/a | 17 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.0001 | n/a | 6 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $39.36 | n/a | 1 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $429.90 | n/a | 48 | Jun 7, 2017 |
Chemed
Nov 12, 2026
Reiterated: Buy
Price Target: $625
Current: $550.20
Upside: +13.60%
PACS Group
Nov 10, 2026
Reiterated: Buy
Price Target: $57
Current: $48.00
Upside: +18.75%
The Cigna Group
Nov 6, 2026
Reiterated: Buy
Price Target: $365
Current: $296.27
Upside: +23.20%
Evolent Health
Nov 6, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.77
Upside: +46.75%
Guardian Pharmacy Services
Nov 6, 2026
Reiterated: Buy
Price Target: $49
Current: $49.38
Upside: -0.77%
The Pennant Group
Nov 5, 2026
Reiterated: Buy
Price Target: $40 → $50
Current: $35.91
Upside: +39.24%
Teladoc Health
Nov 2, 2026
Reiterated: Buy
Price Target: $7 → $10
Current: $8.69
Upside: +15.07%
Community Health Systems
Oct 30, 2026
Reiterated: Buy
Price Target: $4 → $3.5
Current: $2.21
Upside: +58.37%
The Ensign Group
Oct 29, 2026
Reiterated: Buy
Price Target: $210 → $215
Current: $186.55
Upside: +15.25%
Healthcare Services Group
Oct 22, 2026
Reiterated: Buy
Price Target: $28
Current: $25.02
Upside: +11.91%
Oct 9, 2026
Reiterated: Buy
Price Target: $405 → $475
Current: $443.68
Upside: +7.06%
Sep 15, 2026
Initiated Coverage: Buy
Price Target: $53
Current: $31.77
Upside: +66.82%
Jul 27, 2026
Reiterated: Buy
Price Target: $520 → $485
Current: $500.66
Upside: -3.13%
Jul 17, 2026
Rated: Buy
Price Target: $405 → $500
Current: $405.13
Upside: +23.42%
May 6, 2026
Rated: Buy
Price Target: $155
Current: $123.72
Upside: +25.28%
Apr 29, 2026
Rated: Buy
Price Target: $45 → $58
Current: $70.27
Upside: -17.46%
Aug 9, 2024
Reiterated: Hold
Price Target: n/a
Current: $89.79
Upside: n/a
Mar 2, 2023
Reiterated: Buy
Price Target: $3
Current: $0.0001
Upside: n/a
Feb 9, 2018
Reiterated: Buy
Price Target: $35
Current: $39.36
Upside: n/a
Jun 7, 2017
Rated: Hold
Price Target: n/a
Current: $429.90
Upside: n/a